Developing mRNA Vaccines Against Infectious Diseases
During the last two decades, researchers have paid more and more attention to mRNA-based technologies for the development of prophylactic vaccines to combat infectious diseases. With the technological advancements in the mRNA field, such as stability, chemistry and delivery systems, the development of fully synthetic mRNA vaccines has been improved and accelerated. At present, mRNA vaccines against infectious diseases have made promising accomplishments, showing safe, potent and long-lasting immune response in preclinical and clinical trials. To further promote the development of mRNA vaccines against infectious diseases, Creative Biogene provides a range of customized and inventive solutions, involving the development of influenza mRNA vaccines, anti-parasite mRNA vaccines, mRNA vaccines against HIV as well as the global SARS-CoV-2 pandemic. We are committed to exerting the potential of synthetic mRNA as an important vaccine candidate for infectious diseases, hoping to meet our customers' specific requirements for projects at the preclinical stages.
The necessary development of new vaccine technologies against infectious diseases
To date, to prevent and eliminate the transmission of infectious diseases, vaccination might be the most effective among the public health interventions. Since the development of vaccination in the 18th century, they have become the basis of global public health programs and major socioeconomic benefits. Although traditional vaccine methods have progressed, factors such as a long development cycle, complex vaccine production, and high investment costs still hinder conventional vaccine platforms. Besides, conventional vaccine technology platforms are inadequate with the need to develop vaccines for chronic infections as well as emerging diseases. For example, influenza viruses have the characteristic of continuous evolution. Therefore, conventional vaccines need to be reformulated almost every year. Rapid development and large-scale production of new and efficient vaccines against infectious diseases are critically needed.
Creative Biogene is proud to be also working on fighting the novel coronavirus. We strive to promote mRNA vaccine against infectious diseases into clinical trials. Based on the in-depth knowledge of coronavirus and advanced mRNA technologies, we have the capability to produce mRNA vaccines with a rapid and robust immunogenicity profile, which enables efficient within-host antigen production and promotes antibody responses to SARS-CoV-2.
mRNA vaccines have the potential to cope with Influenza owing to its precise antigen design, rapid and flexible manufacturing as well as low-cost maintenance. Our influenza mRNA vaccine platform is based on the multiple conserved epitopes of influenza viruses, aiming to make up for the shortage of traditional vaccines and provide broad and durable protective vaccines.
Caused by the infection of HIV, AIDS is a chronic and life-threatening condition. Nowadays, control of the AIDS epidemic is one of the leading global health priorities. We believe that the development of self-amplifying mRNA will play an important role in mRNA vaccines against HIV soon. Therefore, we have launched a platform to develop self-amplifying mRNA vaccines against HIV.
The mRNA vaccine platform will become ideal for the development of neglected parasitic disease vaccines, owing to its fast, low-cost and large-scale vaccine production. We are committed to developing mRNA vaccine against parasitic infections. Creative Biogene can accelerate and improve our customers' projects in anti-parasite mRNA vaccine development.
If you are interested in our service, please feel free to contact us for more details.
- Maruggi, G., et al. (2019). "mRNA as a transformative technology for vaccine development to control infectious diseases." Molecular Therapy, 27(4), 757-772.
- Zhang, C., et al. (2019). "Advances in mRNA vaccines for infectious diseases." Frontiers in Immunology, 10, 594.